Lymphoma

How to Manage Venetoclax Resistance in Chronic Lymphocytic Leukemia

Experts outline treatment options for patients with venetoclax resistance.

Combination Temsirolimus and Lenalidomide Seems Feasible in Relapsed/Refractory Lymphomas

By

Lauren Dembeck, PhD

Researchers sought to determine whether combination therapy with temsirolimus and lenalidomide would have therapeutic activity in patients with heavily pretreated lymphomas.

Rituximab Biosimilars Produce Comparable Outcomes in Diffuse Large B-Cell Lymphoma

By

Leah Lawrence

Response and survival outcomes were similar with rituximab biosimilars and the originator.

Nivolumab Rechallenge May Benefit Patients With Relapsed, Refractory Hodgkin Lymphoma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether patients with relapsed or refractory classical Hodgkin lymphoma can receive benefit when retreated with nivolumab.

Patients With Lymphoma May Develop Antibodies for COVID-19 Vaccine 6 Months After Treatment

By

Patricia Chaney

Researchers sought to determine whether patients with lymphoma would develop antibodies with a COVID-19 vaccine 6 months after treatment with anti-CD20-containing therapy.

Bone Marrow and Extracellular Vesicles Associated With Development of Follicular Lymphoma B Cells

By

Vicki Moore, PhD

Researchers sought to determine whether there is a role for extracellular vesicles associated with follicular lymphoma B cells in the alteration of bone marrow stroma.

Treatment Impacts on Fertility for Patients With Hodgkin Lymphoma or Diffuse Large B-Cell Lymphoma

By

Vicki Moore, PhD

Researchers sought to determine the fertility-related issues and approaches for survivors of Hodgkin lymphoma and diffuse large B-cell lymphoma.

Baseline SUVmax May Have Prognostic Value in Patients With Follicular Lymphoma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether baseline SUVmax would have prognostic value in patients with follicular lymphoma.

Older Patients With NHL at High Risk for Treatment-Related Toxicity Events

By

Jessica Nye, PhD

A retrospective study revealed age-based risks for toxicities in patients with NHL treated with high-dose chemotherapy and autologous hematopoietic cell transplantation.

Diffuse B-Cell Lymphoma of CNS After Dimethyl Fumarate Treatment in RRMS

By

Brandon May

This case study showed that B-cell type primary central nervous system lymphoma may rapidly progress following dimethyl fumarate treatment in patients with relapsing remitting MS.

Circulating Tumor DNA May Predict Outcomes of CAR T-Cell Therapy in Large B-Cell Lymphoma

By

Sucharita Mistry, PhD

Circulating tumor DNA may identify patients at risk of relapse after axicabtagene ciloleucel.

Intratumoral T-Cells Affect FDG-PET Prognostic Efficacy in Follicular Lymphoma

By

Patricia Chaney

Researchers sought to determine how chemoimmunotherapies can affect FDG-PET parameters and influence interpretation of results in patients with FL.

Primary Central Nervous System Lymphoma May Be Treated by Methotrexate Outside Clinical Trials

By

Patricia Chaney

Researchers sought to determine whether patients with PCNSL who are not eligible for clinical trials may benefit from high-dose methotrexate.

Brentuximab Vedotin May Improve Outcomes in Anaplastic Large Cell Lymphoma

By

Jonathan Goodman, MPhil

Researchers sought to determine whether adding brentuximab vedotin to chemotherapy would be safe and effective in pediatric patients with ALCL.

Low-Cost Transcript-Based Method Developed for Diagnosing Lymphoma Biopsy Samples

By

Vicki Moore, PhD

Researchers sought to develop a low-cost, machine learning-based approach to diagnosing paraffin-embedded lymphoma biopsy specimens.

Diagnostic Features of Nodular Lymphocyte-Predominant Hodgkin Lymphoma

By

Vicki Moore, PhD

In a review, researchers explained diagnostic features associated with the rare condition of nodular lymphocyte-predominant Hodgkin lymphoma.

HDMTX Promising for Patients With Primary CNS Lymphoma Ineligible for Clinical Trials

By

Jennifer Larson

Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.

LRPAP1 Autoantibodies Have Prognostic Value in Mantle Cell Lymphoma

By

Patricia Chaney

Researchers sought to determine whether the presence of LRPAP1 autoantibodies may predict clinical outcomes in patients with MCL.

Gene Expression Shows New Mechanism of Action With Chidamide Therapy in Peripheral T-Cell Lymphoma

By

Vicki Moore, PhD

Researchers sought to identify a new possible immune-related mechanism of action associated with chidamide for treatment of patients with PTCL.

Zanubrutinib Yields Durable Responses in Patients With Relapsed/Refractory Mantle Cell Lymphoma

By

Lauren Dembeck, PhD

Researchers sought to determine whether zanubrutinib would have a high response rate and extended progression-free survival in patients with R/R mantle cell lymphoma.

Novel Model Shows High Predictive Potential in Patients With DLBCL

By

Jonathan Goodman, MPhil

Researchers sought to determine whether a novel model that combines signatures of metabolic dysregulation with clinical features may aid in clinical decision-making among patients with DLBCL.

Fixed-Duration Chemo-Free Treatment Efficacious in Patients With Relapsed/Refractory Waldenström Macroglobulinemia

By

Lauren Dembeck, PhD

Researchers sought to determine whether fixed-duration chemotherapy-free treatment with obinutuzumab and idelalisib would be effective in patients with R/R WM.

Recommended Dose Determined for Loncastuximab Tesirine in B-Cell Non-Hodgkin Lymphoma

By

Patricia Chaney

Researchers sought to determine the maximum and recommended phase 2 dose for loncastuximab tesirine in patients with B-cell NHL.

SYMPATICO Trial: Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma

By

Cancer Therapy Advisor Staff

Researchers are seeking to compare the efficacy and safety of the combination of ibrutinib and venetoclax compared with ibrutinib and placebo in patients with mantle cell lymphoma.

Survival Rates for Allogeneic, Autologous HSCT Are Similar in Patients With R/R Peripheral T-Cell Lymphoma

By

Jessica Nye, PhD

Researchers sought to determine which hematopoietic stem cell transplantation procedure is more efficacious for patients with refractory/relapsed peripheral T-cell lymphoma.

Cognition, Functioning Deficits in Survivors of Pediatric Extracranial Solid Tumors and Lymphomas

By

Bette Weinstein Kaplan

A review of the literature identified common deficits in cognitive functioning experienced by survivors of pediatric cancers.

Potential Prognostic Marker for Extranodal Natural Killer T-Cell Lymphoma

By

Vicki Moore, PhD

Researchers sought to identify possible prognostic markers in extranodal natural killer T-cell lymphoma through an analysis of gene expression profiling data.

Chemotherapy Followed by Autologous Stem Cell Transplantation Shows Promise as First-Line Treatment for T-Cell Non-Hodgkin Lymphoma

By

Patricia Chaney

Researchers sought to determine whether first-line chemotherapy followed by high-dose therapy and auto-SCT would be the preferred treatment for patients under 60 with T-NHL.

Relapsed, Refractory Follicular Lymphoma: CAR-T Cell Therapy Shows Promise

By

Jonathan Goodman, MPhil

In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5.

DLBCL: Naratuximab Shows Promise Among Patients With Relapsed/Refractory Disease

By

Jonathan Goodman, MPhil

The overall response rate was 44.7% after a median follow-up of 15 months.

Tislelizumab Deemed an ‘Important Option’ for Relapsed/Refractory Classical Hodgkin Lymphoma

By

Jonathan Goodman, MPhil

The median overall survival was not reached at 3 years.

MATRIX Provides ‘Excellent, Long-Lasting Survival’ in Primary CNS Lymphoma

By

Jonathan Goodman, MPhil

The 7-year survival results were superior with MATRIX.

Anti-CD20 Therapy Linked to Prolonged Hospital Stay and Death in Lymphoma Patients With COVID-19

By

Jonathan Goodman, MPhil

Relapsed/refractory disease and older age were also associated with prolonged hospital stay and death.

Factors Leading to CAR T Cell Therapy Resistance in Patients With Large B-Cell Lymphoma

By

Vicki Moore, PhD

Researchers sought to identify factors that may contribute to failure with CAR T cell therapy in patients with LBCL.

Non-Hodgkin Lymphoma: Copanlisib Rituximab Combination May Improve Survival

By

Jonathan Goodman, MPhil

Six patients experienced a grade 5 treatment-related adverse event.

Infection-Related Outcomes Relative to R-CHOP Dose in Older Patients With Diffuse Large B-Cell Lymphoma

By

Vicki Moore, PhD

This analysis compared infection-related hospitalization and death among patients 70 years of age and older with DLBCL treated with full-dose vs attenuated-dose R-CHOP.

Zanubrutinib Gets Priority Review for Marginal Zone Lymphoma

By

Brian Park, PharmD

Zanubrutinib is marketed under the trade name Brukinsa and is currently indicated for the treatment of mantle cell lymphoma.

Pirtobrutinib Shows Promising Results in Patients With Heavily Pretreated Mantle Cell Lymphoma

By

Patricia Chaney

Researchers sought to determine whether pirtobrutinib would be effective and tolerable in heavily pretreated patients with mantle cell lymphoma.

Nivolumab Plus Brentuximab Vedotin Shows Efficacy for Patients With Mediastinal Gray Zone Lymphoma

By

Vicki Moore, PhD

Researchers sought to determine whether combining nivolumab with brentuximab vedotin would be safe and effective in treating patients with mediastinal gray zone lymphoma.

Zynlonta Approved for Relapsed/Refractory Large B-Cell Lymphoma

By

Brian Park, PharmD

Zynlonta (loncastuximab tesirine-lpyl) is a CD19-directed antibody and alkylating agent conjugate.

Post-Traumatic Stress Symptoms Seen in Pediatric Hodgkin Lymphoma Survivors

By

Ariela Katz

Researchers sought to investigate the associations between PTSS and the experiences of pediatric survivors of Hodgkin lymphoma treated in the AHOD0031 study.

Change in Health Behaviors Affect Quality of Life in Lymphoma Survivors

By

Andrea S. Blevins Primeau, PhD, MBA

Baseline alcohol consumption was associated with a higher QOL score compared with never use of alcohol.

Ibrutinib Shows Similar Efficacy to RICE/RVICI in Pediatric Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

By

Ariela Katz

Researchers sought to update and assess the interim efficacy, futility, and safety in the phase 3 SPARKLE trial.

MATRix-RICE and Autologous HSCT Beneficial in DLBCL With CNS Involvement

By

Andrea S. Blevins Primeau, PhD, MBA

Investigators report on findings from the MARIETTA study, which evaluated an intensive, CNS-directed chemoimmunotherapy followed by autoHSCT in patients with secondary CNS lymphoma.

Camrelizumab Plus Decitabine Improve Outcomes in Relapsed/Refractory Hodgkin Lymphoma

By

Patricia Chaney

Combination therapy of anti-PD-1 camrelizumab plus decitabine led to longer response in patients with relapsed/refractory Hodgkin lymphoma.

Brentuximab Vedotin Shows Efficacy for Pediatric Patients With Classical Hodgkin Lymphoma

By

Vicki Moore, PhD

Researchers sought to determine the safety and efficacy of brentuximab vedotin in pediatric patients with classical Hodgkin lymphoma.

Engineered Cell Therapy AB-205 Shows Efficacy in Lymphoma With HDT-AHCT

By

Ariela Katz

Researchers sought to determine whether AB-205 would be a safe and effective therapy added to HDT-AHCT in adult patients with lymphoma.

AlloHCT Following Treatment With PD-1 mAbs Beneficial in Classic Hodgkin Lymphoma

By

Colby Stong

An international, retrospective study was conducted to assess outcomes following alloHCT after PD-1 blockade in Hodgkin lymphoma.

Hypomagnesemia at Time of Transplant Associated With Worse Survival in Patients With DLBCL

By

Jonathan Goodman, MPhil

Researchers sought to determine whether hypomagnesemia increases the risk of failure for autologous hematopoietic stem cell transplantation in patients with DLBCL.

Outcomes of PET4-Guided Omission of Radiotherapy Consolidation in Hodgkin Lymphoma

By

Andrea S. Blevins Primeau, PhD, MBA

A team of investigators sought to determine if treatment efficacy can be maintained without radiotherapy among patients with newly diagnosed, early-stage, unfavorable Hodgkin lymphoma.

R-MegaCHOEP vs R-CHOEP-14 in Newly Diagnosed Aggressive B-Cell Lymphoma

By

Vicki Moore, PhD

Researchers sought to determine whether R-MegaCHOEP would improve outcomes compared to R-CHOEP-14 in patients with newly diagnosed, aggressive B-cell lymphoma.